ABVC BioPharma, Inc. (ABVC)

ABVC's stock price has fluctuated in the past six months, closing at $1.60 on February 5, 2026, with a 52-week range between $0.40 and $5.48. In Q3 2025, the company reported a 230% year-over-year increase in licensing revenue, reaching approximately $1.28 million, and total assets increased by 181% to $21.18 million. ABVC received licensing payments from strategic partners, including $240,000 from OncoX BioPharma. The company highlighted strengthened operations at its BioKey subsidiary and the safety profile of its ADHD candidate. The stock price declined by 15.53% over 10 days leading up to February 6, 2026.

The demand seasonality for ABVC BioPharma's products is primarily driven by disease prevalence, ongoing treatment needs, and advancements in drug development rather than strong seasonal fluctuations. The oncology market's demand is driven by cancer incidence and treatment efficacy. The CNS therapeutics market is experiencing a resurgence, with sales projected to increase. The ophthalmology drugs market is growing rapidly due to the rising prevalence of eye disorders.

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company specializing in botanically based solutions with high efficacy and low toxicity. The company focuses on developing new drugs and medical devices, in-licensing compounds from research institutions, particularly plant-derived ones, that address unmet medical needs and have completed Phase I safety studies. ABVC aims to partner with larger pharmaceutical companies for Phase III, NDA submission, and commercialization after successful Phase II trials. ABVC has an active pipeline of six drugs and one medical device under development, targeting oncology/hematology, central nervous system disorders, and ophthalmology.

ABVC BioPharma, Inc. is headquartered in Fremont, California, and conducts clinical trials in the United States, Australia, and Taiwan, collaborating with institutions like Stanford University. The company is developing a "dual-core" operational structure with innovation and clinical development in Silicon Valley and manufacturing and development activities in Taiwan. ABVC has invested in land acquisitions in Taiwan for botanical raw materials and new drug substance research, and plans to invest in constructing "gigafactories" in the U.S. for botanical raw material cultivation and pharmaceutical manufacturing.

No specific information regarding ABVC BioPharma's brand reputation was found in the provided search results. However, one financial media outlet highlighted ABVC BioPharma as one of the "Best Biotech Penny Stocks" in October 2025, recognizing its financial growth and advancing pipeline. Analysts have given ABVC a consensus "Sell" rating.

As of January 2026, ABVC BioPharma, Inc. has 17 institutional owners and shareholders holding a total of 785,330 shares, accounting for approximately 2.04% of the company's stock. Key institutional shareholders include Vanguard Group Inc., Geode Capital Management, LLC, and Renaissance Technologies LLC. Tsung Shann Jiang holds 49.81% of the shares, Shuling Jiang holds 32.55%, and Eugene Jiang holds 3.02%.